NanoString announces launch of Whole Transcriptome Atlas

NanoString Technologies announced the commercial availability of the Whole Transcriptome Atlas for research using human tissue and the GeoMx Digital Spatial Profiler. In addition, NanoString is introducing the WTA for research using mouse tissue through its GeoMx Technology Access Program. These launches extend the GeoMx Atlas portfolio, which combine the power of spatial biology and Next Generation Sequencing, to enable full transcriptome spatial RNA and high-plex protein analysis on the GeoMx DSP. The WTA provides an unbiased, spatial view of all protein-coding genes and is designed for NGS readout on Illumina sequencers. The WTA extends the GeoMx RNA Assay portfolio from a focus on oncology and immunology to new applications in neuroscience, developmental biology, and additional diverse fields. The WTA utilizes the same workflow and chemistry as other GeoMx Atlas products to enable robust and sensitive performance in formalin-fixed paraffin-embedded or Fresh Frozen samples. Complementary protein assays allow for a multi-omic view of spatial biology using GeoMx DSP. The commercial launch of the Whole Transcriptome Atlas will be highlighted at NanoString's 3rd Annual Spatial Genomics Summit, to be held virtually on February 23. Data demonstrating the high sensitivity and robust performance of the WTA for human and mouse will be highlighted in several presentations from leading research institutions. The Spatial Genomics Summit has been held each February beginning in 2019 to showcase the rapidly evolving field of Spatial Genomics. This year's event will include a panel of experts for the plenary roundtable discussion of "Research in the Spatial Genomics Era." Panelists include Drs. Esperanza Anguiano from Bristol Myers Squibb, Omer Bayraktar of the Wellcome Sanger Institute, Evan Newell from the Fred Hutchinson Cancer Research Center and Peter Sorger of Harvard Medical School. The moderator of the panel is Stephane Budel, Ph.D., from DeciBio Consulting.